Skip to Main Content

Paper Details

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Clin Cancer Res
17
2021
CTC, CTCs, Circulating Tumor Cell, Metastatic Castrate-Sensitive Prostate Cancer, PSA, androgen, bicalutamide, circulating tumor cell, mCRPC, mCSPC, men, metastatic castrate-resistant prostate cancer, metastatic castrate-sensitive prostate cancer, orteronel, patient, patients
Author NameAffiliation
Sue A InglesUniversity of Southern California Norris Comprehensive Cancer Center and Keck School of Medicine
Timothy J TricheUniversity of Southern California Norris Comprehensive Cancer Center and Keck School of Medicine
Timothy J TricheUniversity of Southern California Norris Comprehensive Cancer Center and Keck School of Medicine
David J McConkeyJohns Hopkins Greenberg Bladder Cancer Institute
Primo N LaraUC Davis Comprehensive Cancer Center
Maha HussainNorthwestern University
David I QuinnUniversity of Southern California Norris Comprehensive Cancer Center and Keck School of Medicine
Ian M ThompsonChristus Santa Rosa Hospital-Medical Center
Neeraj AgarwalUniversity of Utah Huntsman Cancer Institute
  • 1 - 9

Datasets

Release 1.2